Sucraid is a drug owned by Qol Medical Llc. It is protected by 3 US drug patents filed from 2017 to 2018 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 07, 2034. Details of Sucraid's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US9255261 | Ultrapure hypoallergenic solutions of sacrosidase |
Feb, 2034
(9 years from now) | Active |
| US9849161 | Ultrapure hypoallergenic solutions of sacrosidase |
Feb, 2034
(9 years from now) | Active |
| US9469847 | Ultrapure hypoallergenic solutions of sacrosidase |
Feb, 2034
(9 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Sucraid's patents.
Latest Legal Activities on Sucraid's Patents
Given below is the list of recent legal activities going on the following patents of Sucraid.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 07 Mar, 2024 | US9469847 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 25 Jul, 2023 | US9255261 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 28 Jun, 2021 | US9849161 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 20 Apr, 2020 | US9469847 |
| Post Issue Communication - Certificate of Correction | 24 Feb, 2020 | US9255261 |
| Post Issue Communication - Certificate of Correction | 18 Feb, 2020 | US9469847 |
| Post Issue Communication - Certificate of Correction | 18 Feb, 2020 | US9849161 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 09 Aug, 2019 | US9255261 |
| Patent Issue Date Used in PTA Calculation Critical | 26 Dec, 2017 | US9849161 |
| Recordation of Patent Grant Mailed Critical | 26 Dec, 2017 | US9849161 |
US patents provide insights into the exclusivity only within the United States, but Sucraid is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Sucraid's family patents as well as insights into ongoing legal events on those patents.
Sucraid's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Sucraid's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 07, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Sucraid Generics:
There are no approved generic versions for Sucraid as of now.
About Sucraid
Sucraid is a drug owned by Qol Medical Llc. Sucraid uses Sacrosidase as an active ingredient. Sucraid was launched by Qol Medcl in 1998.
Approval Date:
Sucraid was approved by FDA for market use on 09 April, 1998.
Active Ingredient:
Sucraid uses Sacrosidase as the active ingredient. Check out other Drugs and Companies using Sacrosidase ingredient
Dosage:
Sucraid is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 8,500 IU/ML | SOLUTION | Prescription | ORAL |